Navigation Links
An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
Date:3/8/2013

Toronto, Canada (PRWEB) March 08, 2013

With patient recruitment rates up to twenty times faster than the West, the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical trials in emerging markets such as Russia. In fact, 33% of all drugs approved by the FDA and 48% of all drugs approved by the EMEA in 2011 included data from clinical trial research conducted in this region.

Yet with benefits like this, why isn’t this number closer to 100%? For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of unknown regulatory and logistics requirements, prolonged study start-up times and overall clinical trial quality.

During the webinar, ClinStar CEO David Passov and QA Director Dr. Stanislav Gneushev will evaluate the quality of clinical trials being conducted in Russia / Ukraine compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will:

  •     Discuss key elements of successful Quality Management Systems for niche CROs operating in Russia, Ukraine, Belarus and the Baltics
  •     Provide practical advice on SOP development
  •     Present training approaches for optimal coaching of clinical monitors
  •     Consider what quality assurance activities are required in Russia and parts of Eastern Europe to ensure continuous quality improvement of clinical studies

For more information about this event or to register, visit: http://xtks.in/xto580-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10499405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PhaseRx Announces Technology Evaluation Agreement with Monsanto
2. Evaluation of a Single 1.000 mg Iron Dose as Ferric Carboxymaltose (FCM) for Fatigue Treatment in Iron Deficient Women - PREFER
3. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
4. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
5. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
6. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
7. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
10. Eastern Clinical Trials Russia CRO Passes EMA Inspection
11. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... Appellate Court of New Jersey approved ... filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for its motion ... its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA located in ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced ... - Global Forecast to 2021" report to their offering. ... The biosimilars market ... 3.39 Billion in 2016, at a CAGR of 26.3%. ... product, manufacturing type, and application. Factors such as rising incidence of ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... every cuvette-related demand that it has found among its diverse customer base. The ... for use in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing ...
Breaking Biology Technology:
(Date:12/7/2016)... PUNE, India , December 7, 2016 According to ... NLP, Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End ... size is estimated to grow from USD 6.72 Billion in 2016 to USD ... Continue Reading ... ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):